Anatara Lifesciences Limited announced the appointment of two human health focused directors to the Anatara Lifesciences Board of Directors, with Sue MacLeman joining as Non-Executive Chairman and Dr. Jane Ryan as Non-Executive Director from September 1, 2018. Sue MacLeman will take over the role of Non-Executive Chairman from Dr. Jay Hetzel, who as Interim Chairman has led the Company since the retirement of Dr. Mel Bridges, Co-Founder, Chairman & CEO earlier in the year. Following the commercial decision to focus on the development of products and technologies in the human health sector focused on gut health, the Board has undertaken an extensive search to identify new directors with the relevant background and experience which has resulted in these appointments. Sue has more than 25 years' experience as a pharmaceutical, biotechnology and medical technology executive with senior roles at Schering-Plough Corporation (now Merck) Amgen, Bristol-Myers Squibb and Mesoblast. Sue recently stepped down from her role as Managing Director and Chief Executive Officer of the Medical Technologies and Pharmaceuticals Growth Centre (MTPConnect) where she will take up the role of non- executive chairman later in the year. Jane has over 25 years of international experience in the pharmaceutical and biotechnology industries where she has managed research and development programs and held key roles in business development and alliance management. Jane has worked both in Australia and internationally with companies including Peptech, Roche, Cambridge Antibody Technology and Biota Holdings. As a result of these appointments, Paul Grujic will stand down on August 31 from the Anatara Board and also Dr. Jay Hetzel has indicated he will retire as a Director at the AGM in November 2018 following a successful handover to the new Chair. Iain Ross, non-executive director and Dr. Tracie Ramsdale, who is currently Acting CEO will remain on the Anatara Board. An extensive search to identify a new CEO, with relevant experience is underway.